Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What is it going to take to wake this up?
Touched 24.5 then didn't check the mail. Now the dogs want to sue.
Really, all I want is to trade.
FDA Approval
Now we should see something.
52 week low, after a reverse split
My Dad always said a reverse is a manuever to give a stock more room to fall.
I am watching, be careful!
Merry Christmas!
Thanks
I am also a past holder, crushed, can't be;lieve I am looking for reentry points.
Got some at 0.60 and 0.77.
Thank You Very Much
I am also a longterm crushed holder that is too afraid to calculate what I would need to get even. I am just looking for reentry points.
Som at $0.60 and also at $0.78, and I can't believe I bought back in.
Thank You Very Much
I am also a longterm crushed holder that is too afraid to calculate what I would need to get even. I am just looking for reentry points.
Som at $0.60 and also at $0.78, and I can't believe I bought back in.
Why buy?
Tell us about the VA Deal
What is VDEX?
Who are Mike C and Matt, insiders?
Broke $50 this AM
It is there to stay. Wish I had some $22. stock
I like tasr at this level
I bought in at 23.50 and am looking for a cash out at 25.
You mention round 6, what is your trading range?
I would ask the bank.
All a reverse does is
Give a bad stock more room to fall............
All a reverse does is
Give a bad stock more room to fall............
All a reverse does is
Give a bad stock more room to fall............
Rebalancing Buy? 2 M shares tonight?
really?
http://247wallst.com/healthcare-business/2015/12/01/huge-powershares-etf-rebalance-means-massive-buying-for-4-biotech-stocks/
MannKind
MannKind Corp. (NASDAQ: MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes, and Cowen thinks it will see a massive buy of 2,405,300 shares of stock. That represents 41% of the 10-day average trading volume.
The company has been an incredibly volatile stock over the past few years. MannKind has launched its inhalable insulin product, which was on the burner seemingly forever.
The consensus price target is set at $4.67. MannKind shares closed trading on Monday at $2.
If it really happens it could be my short squeeze.
investopedia has a negative article
I tried to post the link but was blocked.
http://www.investopedia.com/stock-analysis/063015/3-reasons-peregrines-stock-could-fall-pphm.aspx?partner=YahooSA
Anybody see any DTC ADs?
Still looking
Thanks, I installed it. TWT.
Thanks, I will try it.
Do you have a suggestion as to which one?
all the ads are ruining the site.
Every new message takes forever to load waiting for the new loads.
NEXT EVENT IS A 1 FOR 10 REVERSE
They need to do something or get to the PINK SHEETS.
I voted against 75,000,000 more shares.
Dilution is not warranted by performance to date.
Also against changes to mgt incentives.
At what price will SNY make an OFFER?
Everyone talks about Goldman, I don't trust the French.
No Worries? But the stock is below a Buck.
That Great thinker Alfred E Neuman said much the same thing.
I asked Scottrade to not loan my shares for shorting
They acted like I was speaking in a foreign language.
Who has 1st hand info on this with a brokerage house?
They owe me a lot of Money.
I hate to look what I paid, but I moved it from my IRA to my cash account last week at $0.70. Looks like it was a good move.
We need to get back Over $2.00
What bad news dropped it from the $3.00 level?
Just Starting;
About the Phase 3 Trial
Based on a successful Phase 2 trial, which achieved its primary endpoint of disease free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study. According to the National Cancer Institute, over 230,000 women in the U.S. are diagnosed with breast cancer annually. Of these women, about 75% test positive for HER2 (IHC 1+, 2+ or 3+). NeuVax targets approximately 50-60% of HER2-positive patients (IHC 1+/2+ or FISH <2.2) who achieve remission with current standard of care treatment, but have no available HER2-targeted adjuvant treatment options to maintain their disease-free status.
http://www.neuvax.com/about-the-trial/
They are testing a vaccine.
Preliminary Phase 1 and 2 trials have been conducted with NeuVax with the following conclusions:
•Demonstrated an initial Dose Response
•There is a Booster Response?– Evidence suggests that boosters may effect efficacy
•NeuVax plus sargramostim (rhGM-CSF) appears to be well-tolerated and effective at raising HER2 immunity
•NeuVax demonstrated a statistically significant increase in Disease Free Survival (DFS) •Node positive, HER2 1+ and 2+ (Phase 3 target patient population)
•Phase 3 FDA approved SPA (Special Protocol Assessment); established primary endpoint as 36 month DFS/141 events
Answer: 2017?
Maybe we will recover with the other Bio's
I bought more at 3.24.
What a difference a day makes.
Closed at $3.28 Friday. Time to get more.
O Please, Get me some $5.00 MNKD
Cash is waiting.
Too Bad those lookie lookies don't buy
What do you think their interest in looking is?
They can't be seeking info because with all those posts you cannot find any real info.
When is this POC going to go Up?
All it does is slowly drop. I think it is afflicted with a huge lack of interest.
Got back in @ $1,82
Time will tell.
Leave no good deed unpunished
CYTR lets in a compassionate patient, does not qualify for the study and he dies. Last ditch hope did not pan out. I would hope to try anything at that point in a bad situation. But I don't understand the hold on new patients.
700 are in the study
My concern is that it is a vaccine to prevent the recurrence of breast cancer. I think the end point is a couple of years out. But if someone in the group gets cancer is the trial a failure? Does that knock out the legs from the drug?
Lots of unknowns.
Who said anything about shorting?
I am looking for an entry point somewhere below $1.70. They first must start a P 3 study.
Worthless
Do you have a position in MNKD?
Sub $2.00 stock;
Our strategy is to build value for patients and shareholders by:
•
Completing the pivotal Phase 3 randomized, multicenter PRESENT ( P revention of R ecurrence in E arly- S tage, N ode-Positive Breast Cancer with Low-to-Intermediate HER2 E xpression with N euVax T reatment) study of our lead product candidate, NeuVax™ (nelipepimut-S) in 700 patients under a U.S. Food and Drug Administration (FDA)-approved Special Protocol Assessment (SPA); Vacine to prevent cancer. When is the test completed? What if 1 person has a recurrence?
•
Supporting our investigators with completion of the Phase 2b randomized, multicenter, investigator-sponsored clinical trial in 300 HER2 1+ and 2+ breast cancer patients to study NeuVax in combination with Herceptin® (trastuzumab; Genentech/Roche);P2 many years from commercial use
•
Supporting our investigators with initiation and completion of the Phase 2 randomized, multicenter, investigator-sponsored trial to study NeuVax in combination with Herceptin in high-risk HER2 3+ breast cancer patients who have received neoadjuvant therapy;P2 many years from commercial use
•
Supporting our partner, Dr. Reddy’s Laboratories' initiation and completion of the Phase 2 gastric cancer trial with NeuVax in India;P2 many years from commercial use
•
Completing the Phase 2 clinical trial of GALE-301 (folate binding protein (FBP)) cancer immunotherapy in ovarian and endometrial cancer;
•P2 many years from commercial use
Completing a Phase 2 clinical trial with GALE-401 (anagrelide controlled release (CR)) in patients with myeloproliferative neoplasms, including essential thrombocythemia (ET);P2 many years from commercial use
•
Achieving revenue goals for Abstral ® (fentanyl) sublingual tablets, for which we acquired the U.S. rights in March 2013 and launched in the fourth quarter of 2013;Finally revenue, but I have not seen a projection
•
Launching Zuplenz ® (ondansetron) Oral Soluble Film in the U.S. during the first quarter of 2015;See above and
•
Pursuing strategic alliances and acquisitions of other therapeutic products to complement our existing product pipeline and commercialization capabilities.
I don't see any reason for investing now. But I keep it on my watchlist and look for a new entry point.